Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this pilot study is to determine the effects of a 12-week resistance training program on cancer related fatigue in cancer patients receiving tyrosine kinase inhibitor (TKI) therapy. It is hypothesized that incidence and severity of cancer related fatigue can be reduced by exercise training in this population which leads to an improved treatment completion rate.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Strength training group | Experimental | 12 weeks of progressive strength training |
|
| Control group | No Intervention | No intervention |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Progressive strength training | Behavioral | 12 weeks of supervised progressive strength training |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in cancer related fatigue | Assessed via the Multidimensional Fatigue Inventory (MFI). | From baseline to the 6th and 12th week of training. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in muscle strength of the knee extensor, hip flexor and forearm flexor muscles. | Assessed isokinetically and isometrically via an IsoMed2000 test system. | From baseline to the 12th week of training. |
| Change in endurance capacity |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Carsten Grüllich, MD | National Center for Tumor Diseases Heidelberg (GermanCRC/University Hospital Heidelberg) Germany | Principal Investigator |
| Friederike Scharhag-Rosenberger, PhD | National Center for Tumor Diseases Heidelberg (GermanCRC/University Hospital Heidelberg) Germany | Principal Investigator |
| Joachim Wiskamann, PhD | National Center for Tumor Diseases Heidelberg (GermanCRC/University Hospital Heidelberg) Germany | Principal Investigator |
| Dirk Jäger, Professor | National Center for Tumor Diseases Heidelberg (GermanCRC/University Hospital Heidelberg) Germany | Study Chair |
| Karen Steindorf, Professor | National Center for Tumor Diseases Heidelberg (GermanCRC/University Hospital Heidelberg) Germany | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Center for Tumor Diseases Heidelberg (German Cancer Research Center/University Hospital Heidelberg) | Heidelberg | 69120 | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28667563 | Derived | Rosenberger F, Wiskemann J, Vallet S, Haag GM, Schembri E, Jager D, Grullich C. Resistance training as supportive measure in advanced cancer patients undergoing TKI therapy-a controlled feasibility trial. Support Care Cancer. 2017 Dec;25(12):3655-3664. doi: 10.1007/s00520-017-3788-3. Epub 2017 Jun 30. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009043 | Motor Activity |
| D005221 | Fatigue |
| D009369 | Neoplasms |
| ID | Term |
|---|---|
| D001519 | Behavior |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Maximal oxygen uptake (VO2max) assessed in a maximal incremental cycling test.
| From baseline to the 12th week of training. |
| Change in body composition | Assessed via bio-impedance measurement. | From baseline to the 12th week of training |
| Change in quality of life | Assessed via the EORTC QLQ C30. | From baseline to the 6th and 12th week of training. |
| Change in depression | Assessed via "Allgemeine Depressionsskala" (ADS). | From baseline to the 6th and 12th week of training. |
| Time of the first tumor progression under TKI therapy | Within the first 6 months of TKI therapy |
| Time of reduction or replacement of TKI therapy | Within the first 6 months of TKI therapy |